Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia.
作者信息
Patrawala Sara, Ramsey Allison, Capucilli Peter, Tuong Linh-An, Vadamalai Karthik, Mustafa S Shahzad
机构信息
Division of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, NY.
Division of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, NY; Division of Allergy, Immunology and Rheumatology, Rochester Regional Health, Rochester, NY.
出版信息
J Allergy Clin Immunol Pract. 2022 Apr;10(4):1120-1122.e1. doi: 10.1016/j.jaip.2021.12.022. Epub 2022 Jan 1.
PMID:34979334
Abstract
摘要
相似文献
1
Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia.FDA批准的Palforzia花生口服免疫疗法在现实世界中的应用。
J Allergy Clin Immunol Pract. 2022 Apr;10(4):1120-1122.e1. doi: 10.1016/j.jaip.2021.12.022. Epub 2022 Jan 1.
2
Peanut allergen powder (Palforzia).花生过敏原粉末（Palforzia）。
Med Lett Drugs Ther. 2020 Mar 9;62(1593):33-34.
3
Considerations for the Initiation and Implementation of Early Peanut Oral Immunotherapy.早期花生口服免疫疗法启动与实施的考量因素
J Allergy Clin Immunol Pract. 2023 Oct;11(10):3275-3276.e9. doi: 10.1016/j.jaip.2023.06.069.
4
Adverse reactions during peanut oral immunotherapy home dosing.花生口服免疫疗法家庭给药期间的不良反应。
J Allergy Clin Immunol. 2009 Dec;124(6):1351-2. doi: 10.1016/j.jaci.2009.09.042.
5
Peanut oral immunotherapy: Reconsidering a one-size-fits-all approach.花生口服免疫疗法：重新审视一刀切的方法。
Ann Allergy Asthma Immunol. 2022 Sep;129(3):265-266. doi: 10.1016/j.anai.2022.06.018. Epub 2022 Jul 8.
6
Safety and effectiveness of peanut oral immunotherapy in children under 12 months.12个月以下儿童花生口服免疫疗法的安全性和有效性
J Allergy Clin Immunol Pract. 2023 Nov;11(11):3544-3546.e1. doi: 10.1016/j.jaip.2023.07.009. Epub 2023 Jul 14.
7
Evening ingestion as a potential reaction cofactor during peanut oral immunotherapy in children.儿童花生口服免疫疗法期间晚间摄入作为一种潜在的反应辅助因素。
J Allergy Clin Immunol Pract. 2023 Jun;11(6):1964-1966.e2. doi: 10.1016/j.jaip.2023.02.032. Epub 2023 Mar 6.
8
Peanut Oral Immunotherapy: a Current Perspective.花生口服免疫治疗：现状分析。
Curr Allergy Asthma Rep. 2020 Apr 20;20(5):14. doi: 10.1007/s11882-020-00908-6.
9
Peanut Allergen Powder (Palforzia) for Peanut Allergy.用于花生过敏的花生过敏原粉末（Palforzia）
Am Fam Physician. 2022 Jan 1;105(1):20-21.
10
Low dose immunotherapy in very young children to treat peanut allergy.低剂量免疫疗法用于幼儿治疗花生过敏。
Expert Rev Clin Immunol. 2016 Dec;12(12):1251-1253. doi: 10.1080/1744666X.2016.1226131. Epub 2016 Sep 12.
引用本文的文献
1
Omalizumab in food allergy: Risks and benefits.奥马珠单抗治疗食物过敏：风险与益处。
J Food Allergy. 2024 Aug 1;7(1):7-13. doi: 10.2500/jfa.2025.7.250004. eCollection 2024 Aug.
2
Inequalities in Access to Specialist Allergy Services in the United Kingdom: A Report From the BSACI Registry for Immunotherapy (BRIT).英国专科过敏服务获取方面的不平等：英国变态反应与临床免疫学会免疫治疗注册处（BRIT）的报告
Clin Exp Allergy. 2025 Jun;55(6):458-468. doi: 10.1111/cea.70034. Epub 2025 Apr 1.
3
The role of pediatricians in the diagnosis and management of IgE-mediated food allergy: a review.儿科医生在IgE介导的食物过敏诊断和管理中的作用：综述
Front Pediatr. 2024 May 30;12:1373373. doi: 10.3389/fped.2024.1373373. eCollection 2024.
4
Sustained silencing peanut allergy by xanthopurpurin is associated with suppression of peripheral and bone marrow IgE-producing B cell.黄嘌呤通过抑制外周血和骨髓 IgE 产生 B 细胞从而实现对花生过敏的持续抑制。
Front Immunol. 2024 Feb 6;15:1299484. doi: 10.3389/fimmu.2024.1299484. eCollection 2024.
5
Palforzia for Peanut Allergy: A Narrative Review and Update on a Novel Immunotherapy.用于花生过敏的Palforzia：一种新型免疫疗法的叙述性综述与更新
Cureus. 2023 Dec 13;15(12):e50485. doi: 10.7759/cureus.50485. eCollection 2023 Dec.
6
Measuring the Impact of Food Immunotherapy on Health-Related Quality of Life in Clinical Trials.在临床试验中测量食物免疫疗法对健康相关生活质量的影响。
Front Allergy. 2022 Jul 12;3:941020. doi: 10.3389/falgy.2022.941020. eCollection 2022.
7
Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.将首个获批的花生过敏口服免疫疗法应用于临床实践的八点建议。
Allergy Asthma Clin Immunol. 2022 May 9;18(1):37. doi: 10.1186/s13223-022-00671-5.
Zotero 插件